Back to today’s briefing

Story perspectives

Study Reveals Azelastine Nasal Spray Cuts COVID Infections

10/1/2025

22 5

Summary

Story summary

A German clinical trial suggests azelastine nasal spray may reduce COVID-19 and other respiratory infections.
The study enrolled 450 healthy volunteers for 56 days, comparing azelastine to placebo.
COVID-19 infections were 2.2% with azelastine vs 6.7% with placebo; rhinovirus infections also declined.
Limitations include a small sample and funding bias; vaccination and indoor air quality remain primary defenses.

1 of 1

Story summary

A German clinical trial suggests azelastine nasal spray may reduce COVID-19 and other respiratory infections.
The study enrolled 450 healthy volunteers for 56 days, comparing azelastine to placebo.
COVID-19 infections were 2.2% with azelastine vs 6.7% with placebo; rhinovirus infections also declined.
Limitations include a small sample and funding bias; vaccination and indoor air quality remain primary defenses.